Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is benign notochordal cell tumor?
Before birth, a structure called the notochord guides the spine to form, then mostly disappears. Tiny clusters of notochord cells can remain inside the bones of the spine and skull base. When these cells form a small, contained growth, it is called a benign notochordal cell tumor (BNCT). These are almost always discovered by accident on an MRI or CT done for another reason, and they typically cause no pain or problems. They sit entirely within the bone, stay small, and do not invade surrounding tissue. The important reason doctors pay attention to them is their close cousin: chordoma, a malignant tumor that arises from the same notochord cells. BNCT is thought to be a possible precursor to chordoma, so the goal is to confidently tell the two apart — a benign tumor that can simply be watched, versus a cancer that needs aggressive surgery and high-dose radiation.
The main types
Doctors group benign notochordal cell tumor by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Benign notochordal cell tumor (BNCT) | A small, harmless growth confined within the bone, with no destruction or soft-tissue mass. Usually just monitored. |
| Chordoma (the malignant relative) | A cancer from the same notochord cells that destroys bone and forms a soft-tissue mass. It is treated very differently — see our chordoma guide. |
Staging, in plain terms
Because a benign notochordal cell tumor is not a cancer, it has no TNM stage. Instead, doctors focus on imaging features that separate a harmless BNCT from a true chordoma, since that distinction completely changes what happens next.
| No formal cancer stage — benign vs. malignant distinction | What it generally means |
|---|---|
| Typical benign features | Smaller than about 35 mm, stays inside the bone, no bone destruction, no contrast enhancement, and no soft-tissue mass. These reassuring signs point to a benign tumor that can be watched. |
| Indeterminate features | Some imaging findings are unclear. Closer follow-up imaging — and occasionally a biopsy — helps confirm it is not a chordoma. |
| Worrisome / chordoma-like features | Bone destruction, a soft-tissue mass extending outside the bone, or contrast enhancement suggest chordoma rather than a benign tumor, and call for specialist evaluation. |
The standard of care
Benign Notochordal Cell Tumor is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Imaging surveillance (the usual approach)
For a classic benign notochordal cell tumor, the standard is simply to watch it with periodic MRI scans. Most never change and never need treatment.
No routine surgery or biopsy
Because these tumors are harmless and confined to the bone, surgery and even biopsy are usually unnecessary and are avoided unless imaging is worrying.
Specialist review if features change
If a lesion grows, breaks out of the bone, or develops a soft-tissue mass, it is evaluated at a sarcoma or skull-base center to rule out chordoma.
How radiation treatment works
Radiation is not part of treating a benign notochordal cell tumor, because the growth is harmless and does not need to be destroyed. If, however, follow-up reveals that a lesion is actually a chordoma, radiation becomes very important: chordomas resist ordinary x-rays, so doctors use high-dose proton or carbon-ion beams, which deliver intense radiation precisely to the tumor and then stop, protecting the spinal cord and brainstem just millimeters away. That treatment is painless, given in short daily sessions, and leaves no radioactivity in the body.
The main ways radiation is delivered for benign notochordal cell tumor:
Radiation — not used for benign tumors
A true benign notochordal cell tumor needs no radiation. Radiation enters the picture only if the lesion turns out to be a chordoma, where high-dose proton or carbon-ion beams are central to treatment.
MRI monitoring
Repeat MRI is the key tool. It tracks size and signal characteristics over time so any shift toward chordoma-like behavior is caught early, before symptoms develop.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Imaging of chordoma and benign notochordal cell tumor: Radiologic-pathologic studies define the features that separate BNCT (small, intraosseous, no enhancement) from chordoma (bone destruction, soft-tissue mass), guiding when a lesion can be safely watched.[1]
Skeletal Radiology, 2022 (PubMed 36063190)
Systematic review of BNCT management: A systematic review concluded that biopsy and surgery are usually not warranted for benign notochordal cell tumors; imaging surveillance is appropriate unless the lesion shows extraosseous disease.[2]
Systematic review, ScienceDirect (World Neurosurgery)
BNCT as a possible chordoma precursor: Pathology studies show BNCT and chordoma can coexist within the same lesion, supporting the idea that benign notochordal tumors may be precursors to chordoma and reinforcing the value of careful follow-up.[3]
Distinguishing BNCT from chordoma, PMC2257990
Common questions
I was told I have a notochordal tumor — is it cancer? A benign notochordal cell tumor is not cancer. It is a harmless cluster of leftover embryonic cells inside a bone. The reason your doctor is paying attention is that it shares an origin with chordoma, a cancer, so they want to be sure which one you have.
Do I need surgery or radiation? Usually neither. The standard for a classic benign notochordal cell tumor is to monitor it with periodic MRI scans. Surgery and radiation are reserved for lesions that turn out to be — or change into — chordoma.
How will my doctor know if it becomes a chordoma? Follow-up MRIs look for warning signs: growth, destruction of the surrounding bone, contrast enhancement, or a mass pushing outside the bone. If any appear, you'll be referred to a specialist center for evaluation and, if needed, treatment.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.